Edesa Biotech, Inc. (EDSA)
Market Cap | 13.54M |
Revenue (ttm) | n/a |
Net Income (ttm) | -7.25M |
Shares Out | 3.22M |
EPS (ttm) | -2.37 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,376 |
Open | 4.306 |
Previous Close | 4.380 |
Day's Range | 4.200 - 4.306 |
52-Week Range | 2.460 - 8.330 |
Beta | 0.87 |
Analysts | Strong Buy |
Price Target | 39.00 (+828.57%) |
Earnings Date | Aug 7, 2024 |
About EDSA
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic cont... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for EDSA stock is "Strong Buy." The 12-month stock price forecast is $39.0, which is an increase of 828.57% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/5/q/press19-2492635.jpg)
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expecte...
![](https://cdn.snapi.dev/images/v1/6/g/press11-2424966.jpg)
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disease...
![](https://cdn.snapi.dev/images/v1/c/a/conf2-2367206.jpg)
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea...
![](https://cdn.snapi.dev/images/v1/c/a/conf10-2352080.jpg)
Edesa Biotech to Participate in Upcoming Investor Conferences
TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
![](https://cdn.snapi.dev/images/v1/b/f/press20-2336347.jpg)
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
TORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory disea...
![](https://cdn.snapi.dev/images/v1/u/q/conf10-2313108.jpg)
Edesa Biotech to Participate in Barclays Global Healthcare Conference
TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
![](https://cdn.snapi.dev/images/v1/6/k/press2-2307368.jpg)
Edesa Biotech to Participate in Upcoming Dermatology Meetings
TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseas...
![](https://cdn.snapi.dev/images/v1/m/y/press17-2270068.jpg)
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dis...
![](https://cdn.snapi.dev/images/v1/m/a/press4-2217308.jpg)
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
TORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory dise...
![](https://cdn.snapi.dev/images/v1/v/c/press2-2198702.jpg)
Edesa Biotech Reports Fiscal Year 2023 Results
TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory di...
![](https://cdn.snapi.dev/images/v1/k/d/press4-2166017.jpg)
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:...
![](https://cdn.snapi.dev/images/v1/3/j/conf7-2124087.jpg)
Edesa Biotech to Present at Dermatology Drug Development Summit
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr...
![](https://cdn.snapi.dev/images/v1/q/x/press1-2119775.jpg)
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that He...
![](https://cdn.snapi.dev/images/v1/n/g/press16-2101222.jpg)
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-s...
![](https://cdn.snapi.dev/images/v1/y/a/press12-2101216.jpg)
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitmen...
![](https://cdn.snapi.dev/images/v1/i/g/press17-2096793.jpg)
Edesa Biotech Announces One-for-Seven Reverse Share Split
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseas...
![](https://cdn.snapi.dev/images/v1/z/1/press15-2081638.jpg)
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ACCE...
![](https://cdn.snapi.dev/images/v1/w/p/press10-2015682.jpg)
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial ...
![](https://cdn.snapi.dev/images/v1/j/x/press18-1988925.jpg)
Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
TORONTO, ON / ACCESSWIRE / July 26, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the c...
![](https://cdn.snapi.dev/images/v1/z/b/press10-1951129.jpg)
Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Positive Findings Support Potential Expanded Uses for Paridiprubart TORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on ...
![](https://cdn.snapi.dev/images/v1/y/y/press19-1949380.jpg)
Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the c...
![](https://cdn.snapi.dev/images/v1/u/u/press8-1935368.jpg)
Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name
TORONTO, ON / ACCESSWIRE / June 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today the assign...
![](https://cdn.snapi.dev/images/v1/y/l/press5-1886402.jpg)
Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial re...
![](https://cdn.snapi.dev/images/v1/w/y/press1-1845643.jpg)
Edesa Biotech to Participate in Swiss Biotech Day
TORONTO, ON / ACCESSWIRE / April 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the ...
![](https://cdn.snapi.dev/images/v1/h/u/press15-1824926.jpg)
The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
International name assignment is a key step in Edesa's development and commercialization plans TORONTO, ON / ACCESSWIRE / April 4, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmac...